HC Wainwright Has Bearish Forecast for GPCR Q3 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Stock analysts at HC Wainwright cut their Q3 2026 earnings estimates for Structure Therapeutics in a research note issued to investors on Friday, August 7th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.50) per share for the quarter, down from their prior estimate of ($0.37). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($1.84) EPS.

Several other equities analysts have also recently issued reports on GPCR. Wall Street Zen cut Structure Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday. Citizens Jmp decreased their price objective on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research report on Friday. Finally, Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Price Performance

GPCR opened at $53.81 on Tuesday. The stock has a market cap of $3.82 billion, a P/E ratio of -53.81 and a beta of -1.43. The stock’s 50 day simple moving average is $47.94 and its 200 day simple moving average is $53.69. Structure Therapeutics has a 1-year low of $16.00 and a 1-year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10).

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC acquired a new stake in Structure Therapeutics in the 1st quarter valued at $28,000. State of Wyoming acquired a new stake in Structure Therapeutics in the second quarter valued at approximately $28,000. CWM LLC grew its position in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares in the last quarter. Assetmark Inc. raised its stake in shares of Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after purchasing an additional 449 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Structure Therapeutics during the fourth quarter valued at approximately $127,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.